Large animal models for pain therapeutic development

Translational Pain Research: From Mouse to Man

Volumn , Issue , 2009, Pages 371-390

  Henze, Darrell A ^a   Urban, Mark O ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057704356     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (85)

1. Adams, C. P., and V. V. Brantner. 2006. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff. (Millwood.) 25, no. 2:420–428.
2. Ali, Z., M. Ringkamp, T. V. Hartke, H. F. Chien, N. A. Flavahan, J. N. Campbell, and R. A. Meyer. 1999. Uninjured C-fiber nociceptors develop spontaneous activity and alphaadrenergic sensitivity following L6 spinal nerve ligation in monkey. J. Neurophysiol. 81, no. 2:455–466.
3. Arezzo, J. C., J. Rosenstock, L. Lamoreaux, and L. Pauer. 2008. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC. Neurol. 8:33.
4. Beggs, S., and M. W. Salter. 2006. Neuropathic pain: symptoms, models, and mechanisms. Drug Dev. Res. 67, no. 4:289–301.
5. Bennett, G. J., and Y. K. Xie. 1988. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33, no. 1:87–107.
6. Bishop, T., D. W. Hewson, P. K. Yip, M. S. Fahey, D. Dawbarn, A. R. Young, and S. B. McMahon. 2007. Characterisation of ultraviolet-B-induced inflammation as a model of hyperalgesia in the rat. Pain 131, no. 1–2:70–82.
7. Blackburn-Munro, G. 2004. Pain-like behaviours in animals—how human are they? Trends Pharmacol. Sci. 25, no. 6:299–305.
8. Borer, L. R., J. E. Peel, W. Seewald, P. Schawalder, and D. E. Spreng. 2003. Effect of carprofen, etodolac, meloxicam, or butorphanol in dogs with induced acute synovitis. Am. J. Vet. Res. 64, no. 11:1429–1437.
9. Boyce, S., and Hill R.G. 2000. Discrepant results from preclinical and clinical studies on the potential of substance P–receptor antagonist compounds as analgesics. In Proc 9th World Congress on Pain, edited by Devor, M. ISAP Press.
10. Bramwell, S., J. Jink, L. Corradini, H. Rees, S. England, I. Machin, and G. Burgess. Streptozotocin-induced mechanical hyperalgesia in the rat is not a model of diabetic neuropathy. 2007 Neuroscience Meeting Planner Online. [Program No. 181.8]. 2007. Ref Type: Abstract.
11. Brennan, T. J., E. P. Vandermeulen, and G. F. Gebhart. 1996. Characterization of a rat model of incisional pain. Pain 64, no. 3:493–501.
12. Brown, D. C., R. C. Boston, J. C. Coyne, and J. T. Farrar. 2007. Development and psychometric testing of an instrument designed to measure chronic pain in dogs with osteoarthritis. Am. J. Vet. Res. 68, no. 6:631–637.
13. Brown, D. C., R. C. Boston, J. C. Coyne, and J. T. Farrar. 2008. Ability of the canine brief pain inventory to detect response to treatment in dogs with osteoarthritis. Javma —Journal of the American Veterinary Medical Association 233, no. 8:1278–1283.
14. Budsberg, S. C. 2001. Long-term temporal evaluation of ground reaction forces during development of experimentally induced osteoarthritis in dogs. Am. J. Vet. Res. 62, no. 8:1207–1211.
15. Budsberg, S. C., S. A. Johnston, P. D. Schwarz, C. E. DeCamp, and R. Claxton. 1999. Efficacy of etodolac for the treatment of osteoarthritis of the hip joints in dogs. J. Am. Vet. Med. Assoc. 214, no. 2:206–210.
16. Butelman, E. R., J. W. Ball, T. J. Harris, and M. J. Kreek. 2003. Topical capsaicin-induced allodynia in unanesthetized primates: pharmacological modulation. J. Pharmacol. Exp. Ther. 306, no. 3:1106–1114.
17. Butelman, E. R., S. S. Negus, M. B. Gatch, K. J. Chang, and J. H. Woods. 1995. BW373U86, a delta-opioid receptor agonist, reverses bradykinin-induced thermal allodynia in rhesus monkeys. Eur. J. Pharmacol. 277, no. 2–3:285–287.
18. Carlton, S. M., H. A. Lekan, S. H. Kim, and J. M. Chung. 1994. Behavioral manifestations of an experimental model for peripheral neuropathy produced by spinal nerve ligation in the primate. Pain 56, no. 2:155–166.
19. Carlton, S. M., H. Rees, K. Gondesen, and W. D. Willis. 1997. Dextrorphan attenuates responses of spinothalamic tract cells in normal and nerve-injured monkeys. Neurosci. Lett. 229, no. 3:169–172.
20. Chateauvert, J., K. P. Pritzker, M. J. Kessler, and M. D. Grynpas. 1989. Spontaneous osteoarthritis in rhesus macaques. I. Chemical and biochemical studies. J. Rheumatol. 16, no. 8:1098–1104.
21. Chateauvert, J. M., M. D. Grynpas, M. J. Kessler, and K. P. Pritzker. 1990. Spontaneous osteoarthritis in rhesus macaques. II. Characterization of disease and morphometric studies. J. Rheumatol. 17, no. 1:73–83.
22. Cross, A. R., S. C. Budsberg, and T. J. Keefe. 1997. Kinetic gait analysis assessment of meloxicam efficacy in a sodium urate-induced synovitis model in dogs. Am. J. Vet. Res. 58, no. 6:626–631.
23. Davies, S. L., C. Siau, and G. J. Bennett. 2005. Characterization of a model of cutaneous inflammatory pain produced by an ultraviolet irradiation-evoked sterile injury in the rat. J. Neurosci. Methods 148, no. 2:161–166.
24. Dedrick, D. K., S. A. Goldstein, K. D. Brandt, B. L. O’Connor, R. W. Goulet, and M. Albrecht. 1993. A longitudinal study of subchondral plate and trabecular bone in cruciate-deficient dogs with osteoarthritis followed up for 54 months. Arthritis Rheum. 36, no. 10:1460–1467.
25. Dirks, J., K. L. Petersen, M. C. Rowbotham, and J. B. Dahl. 2002. Gabapentin suppresses cutaneous hyperalgesia following heat-capsaicin sensitization. Anesthesiology 97, no. 1:102–107.
26. Drag, M., B. N. Kunkle, D. Romano, and P. D. Hanson. 2007. Firocoxib efficacy preventing urate-induced synovitis, pain, and inflammation in dogs. Vet. Ther. 8, no. 1:41–50.
27. Dubuisson, D., and S. G. Dennis. 1977. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 4, no. 2:161–174.
28. Dykstra, L. A., and J. H. Woods. 1986. A tail withdrawal procedure for assessing analgesic activity in rhesus monkeys. J. Pharmacol. Methods 15, no. 3:263–269.
29. Fernihough, J., C. Gentry, M. Malcangio, A. Fox, J. Rediske, T. Pellas, B. Kidd, S. Bevan, and J. Winter. 2004. Pain related behaviour in two models of osteoarthritis in the rat knee. Pain 112, no. 1–2:83–93.
30. Field, M. J., S. McCleary, J. Hughes, and L. Singh. 1999. Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain 80, no. 1–2:391–398.
31. Fox, A., C. Eastwood, C. Gentry, D. Manning, and L. Urban. 1999. Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat. Pain 81, no. 3:307–316.
32. Hamilton, S. M., S. A. Johnston, and R. V. Broadstone. 2005. Evaluation of analgesia provided by the administration of epidural ketamine in dogs with a chemically induced synovitis. Vet. Anaesth. Analg. 32, no. 1:30–39.
33. Hargreaves, K., R. Dubner, F. Brown, C. Flores, and J. Joris. 1988. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32, no. 1:77–88.
34. Harrison, G. I., A. R. Young, and S. B. McMahon. 2004. Ultraviolet radiation-induced inflammation as a model for cutaneous hyperalgesia. J. Invest. Dermatol. 122, no. 1:183–189.
35. Hawkinson, J. E., B. G. Szoke, A. W. Garofalo, D. S. Hom, H. Zhang, M. Dreyer, J. Y. Fukuda, et al. 2007. Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958. J. Pharmacol. Exp. Ther. 322, no. 2:619–630.
36. Hazewinkel, H. A., W. E. van den Brom, L. F. Theijse, M. Pollmeier, and P. D. Hanson. 2003. Reduced dosage of ketoprofen for the short-term and long-term treatment of joint pain in dogs. Vet. Rec. 152, no. 1:11–14.
37. Hershey, J. C., H. A. Corcoran, E. P. Baskin, C. A. Salvatore, S. Mosser, T. M. Williams, K. S. Koblan, R. J. Hargreaves, and S. A. Kane. 2005. Investigation of the species selectivity of a nonpeptide CGRP receptor antagonist using a novel pharmacodynamic assay. Regul. Pept. 127, no. 1–3:71–77.
38. Hill, R. 2000. NK1 (substance P) receptor antagonists—why are they not analgesic in humans? Trends Pharmacol. Sci. 21, no. 7:244–246.
39. Joshi, S. K., G. Hernandez, J. P. Mikusa, C. Z. Zhu, C. Zhong, A. Salyers, C. T. Wismer, P. Chandran, M. W. Decker, and P. Honore. 2006. Comparison of antinociceptive actions of standard analgesics in attenuating capsaicin and nerve-injury-induced mechanical hypersensitivity. Neuroscience 143, no. 2:587–596.
40. Kessler, M. J., J. E. Turnquist, K. P. Pritzker, and W. T. London. 1986. Reduction of passive extension and radiographic evidence of degenerative knee joint diseases in cage-raised and free-ranging aged rhesus monkeys (Macaca mulatta). J. Med. Primatol. 15, no. 1:1–9.
41. Kim, S. H., and J. M. Chung. 1992. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50, no. 3:355–363.
42. Ko, M.-C., E. R. Butelman, and J. H. Woods. 1998. The role of peripheral mu opioid receptors in the modulation of capsaicin-induced thermal nociception in rhesus monkeys. J. Pharmacol. Exp. Ther. 286, no. 1:150–156.
43. Ko, M.-C. and H. Lee. 2002. An experimental model of inflammatory pain in monkeys: comparison of antinociceptive effects of opioids and NSAIDs against carageenan-induced thermal hyperalgesia. In 10th World Congress on Pain (Seattle: ISAP Press).
44. Kola, I., and J. Landis. 2004. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, no. 8:711–715.
45. Le Bars, D., M. Gozariu, and S. W. Cadden. 2001. Animal models of nociception. Pharmacol. Rev. 53, no. 4:597–652.
46. Lin, J. H. 1999. Role of pharmacokinetics in the discovery and development of indinavir. Adv. Drug Deliv. Rev. 39, no. 1–3:33–49.
47. Lopez, M. J., D. Kunz, R. Vanderby Jr., D. Heisey, J. Bogdanske, and M. D. Markel. 2003. A comparison of joint stability between anterior cruciate intact and deficient knees: a new canine model of anterior cruciate ligament disruption. J. Orthop. Res. 21, no. 2:224–230.
48. Marshall, K. W., and A. D. Chan. 1996. Arthroscopic anterior cruciate ligament transection induces canine osteoarthritis. J. Rheumatol. 23, no. 2:338–343.
49. McCann, M. E., D. R. Andersen, D. Zhang, C. Brideau, W. C. Black, P. D. Hanson, and G. J. Hickey. 2004. In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. Am. J. Vet. Res. 65, no. 4:503–512.
50. McCarty, D. J., Jr., P. Phelps, and J. Pyenson. 1966. Crystal-induced inflammation in canine joints. I. An experimental model with quantification of the host response. J. Exp. Med. 124, no. 1:99–114.
51. McDevitt, C., E. Gilbertson, and H. Muir. 1977. An experimental model of osteoarthritis; early morphological and biochemical changes. J. Bone Joint Surg. Br. 59, no. 1:24–35.
52. Millan, M. J. 1999. The induction of pain: an integrative review. Prog. Neurobiol. 57, no. 1:1–164.
53. Millis, D. L., J. P. Weigel, T. Moyers, and F. C. Buonomo. 2002. Effect of deracoxib, a new COX-2 inhibitor, on the prevention of lameness induced by chemical synovitis in dogs. Vet. Ther. 3, no. 4:453–464.
54. Negus, S. S., E. R. Butelman, Y. Al, and J. H. Woods. 1993. Prostaglandin E2-induced thermal hyperalgesia and its reversal by morphine in the warm-water tail-withdrawal procedure in rhesus monkeys. J. Pharmacol. Exp. Ther. 266, no. 3:1355–1363.
55. Negus, S. S., T. W. Vanderah, M. R. Brandt, E. J. Bilsky, L. Becerra, and D. Borsook. 2006. Preclinical assessment of candidate analgesic drugs: recent advances and future challenges. J. Pharmacol. Exp. Ther. 319, no. 2:507–514.
56. O’Connor, B. L., D. M. Visco, K. D. Brandt, M. Albrecht, and A. B. O’Connor. 1993. Sensory nerves only temporarily protect the unstable canine knee joint from osteoarthritis. Evidence that sensory nerves reprogram the central nervous system after cruciate ligament transection. Arthritis Rheum. 36, no. 8:1154–1163.
57. Obrosova, I. G., O. Ilnytska, V. V. Lyzogubov, I. A. Pavlov, N. Mashtalir, J. L. Nadler, and V. R. Drel. 2007. High-fat diet induced neuropathy of pre-diabetes and obesity: effects of “healthy” diet and aldose reductase inhibition. Diabetes 56, no. 10:2598–2608.
58. Palecek, J., P. M. Dougherty, S. H. Kim, V. Paleckova, H. Lekan, J. M. Chung, S. M. Carlton, and W. D. Willis. 1992. Responses of spinothalamic tract neurons to mechanical and thermal stimuli in an experimental model of peripheral neuropathy in primates. J. Neurophysiol. 68, no. 6:1951–1966.
59. Palecek, J., V. Neugebauer, S. M. Carlton, S. Iyengar, and W. D. Willis. 2004. The effect of a kainate GluR5 receptor antagonist on responses of spinothalamic tract neurons in a model of peripheral neuropathy in primates. Pain 111, no. 1–2:151–161.
60. Pare, M., P. J. Albrecht, C. J. Noto, N. L. Bodkin, G. L. Pittenger, D. J. Schreyer, X. T. Tigno, B. C. Hansen, and F. L. Rice. 2007. Differential hypertrophy and atrophy among all types of cutaneous innervation in the glabrous skin of the monkey hand during aging and naturally occurring type 2 diabetes. J. Comp. Neurol. 501, no. 4:543–567.
61. Peterson, K. D., and T. J. Keefe. 2004. Effects of meloxicam on severity of lameness and other clinical signs of osteoarthritis in dogs. J. Am. Vet. Med. Assoc. 225, no. 7:1056–1060.
62. Pond, M. J., and G. Nuki. 1973. Experimentally-induced osteoarthritis in the Dog. Ann. Rheum. Dis. 32:387–388.
63. Punke, J. P., A. L. Speas, L. R. Reynolds, R. F. Claxton, and S. C. Budsberg. 2007. Kinetic gait and subjective analysis of the effects of a tachykinin receptor antagonist in dogs with sodium urate-induced synovitis. Am. J. Vet. Res. 68, no. 7:704–708.
64. Rice, A. S., D. Cimino-Brown, J. C. Eisenach, V. K. Kontinen, M. L. Lacroix-Fralish, I. Machin, J. S. Mogil, and T. Stohr. 2008. Animal models and the prediction of efficacy in clinical trials of analgesic drugs: a critical appraisal and call for uniform reporting standards. Pain 139, no. 2:243–247.
65. Rukwied, R., M. Dusch, M. Schley, E. Forsch, and M. Schmelz. 2008. Nociceptor sensitization to mechanical and thermal stimuli in pig skin in vivo. Eur. J. Pain 12, no. 2:242–250.
66. Rumph, P. F., S. A. Kincaid, D. K. Baird, J. R. Kammermann, D. M. Visco, and L. F. Goetze. 1993. Vertical ground reaction force distribution during experimentally induced acute synovitis in dogs. Am. J. Vet. Res. 54, no. 3:365–369.
67. Ryan, W. G., K. Moldave, and D. Carithers. 2006. Clinical effectiveness and safety of a new NSAID, firocoxib: a 1,000 dog study. Vet. Ther. 7, no. 2:119–126.
68. Salvatore, C. A., J. C. Hershey, H. A. Corcoran, J. F. Fay, V. K. Johnston, E. L. Moore, S. D. Mosser, et al. 2008. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6- (2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro- 1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carbox amide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J. Pharmacol. Exp. Ther. 324, no. 2:416–421.
69. Scholz, J., and C. J. Woolf. 2007. The neuropathic pain triad: neurons, immune cells and glia. Nat. Neurosci. 10, no. 11:1361–1368.
70. Smith, G. K., P. D. Mayhew, A. S. Kapatkin, P. J. McKelvie, F. S. Shofer, and T. P. Gregor. 2001. Evaluation of risk factors for degenerative joint disease associated with hip dysplasia in German Shepherd dogs, Golden Retrievers, Labrador Retrievers, and Rottweilers. J. Am. Vet. Med. Assoc. 219, no. 12:1719–1724.
71. Stein, C., M. J. Millan, and A. Herz. 1988. Unilateral inflammation of the hindpaw in rats as a model of prolonged noxious stimulation: alterations in behavior and nociceptive thresholds. Pharmacol. Biochem. Behav. 31, no. 2:455–51.
72. Steiner, S., Y. Lu, J. P. Menetski, M. Milovancev, B. Nemke, and M. D. Markel. 2009. Effects of firocoxib therapy on progression of osteoarthris in a canine model. Curr. Orthop. Practice. 20, no. 3:304–312.
73. Sugimoto, K., I. B. Rashid, K. Kojima, M. Shoji, J. Tanabe, N. Tamasawa, T. Suda, and M. Yasujima. 2008. Time course of pain sensation in rat models of insulin resistance, type 2 diabetes, and exogenous hyperinsulinaemia. Diabetes Metab. Res. Rev. 24, no. 8:642–650.
74. Sycha, T., B. Gustorff, S. Lehr, A. Tanew, H. G. Eichler, and L. Schmetterer. 2003. A simple pain model for the evaluation of analgesic effects of NSAIDs in healthy subjects. Br. J. Clin. Pharmacol. 56, no. 2:165–172.
75. Urban, M. O., K. Ren, K. T. Park, B. Campbell, N. Anker, B. Stearns, J. Aiyar, M. Belley, C. Cohen, and L. Bristow. 2005. Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action. J. Pharmacol. Exp. Ther. 313, no. 3:1209–1216.
76. Vareniuk, I., I. A. Pavlov, V. R. Drel, V. V. Lyzogubov, O. Ilnytska, S. R. Bell, J. Tibrewala, J. T. Groves, and I. G. Obrosova. 2007. Nitrosative stress and peripheral diabetic neuropathy in leptin-deficient (ob/ob) mice. Exp. Neurol. 205, no. 2:425–436.
77. Vasseur, P. B., A. L. Johnson, S. C. Budsberg, J. D. Lincoln, J. P. Toombs, J. G. Whitehair, and E. L. Lentz. 1995. Randomized, controlled trial of the efficacy of carprofen, a nonsteroidal anti-inflammatory drug, in the treatment of osteoarthritis in dogs. J. Am. Vet. Med. Assoc. 206, no. 6:807–811.
78. Walker, K., A. J. Fox, and L. A. Urban. 1999. Animal models for pain research. Mol. Med. Today 5, no. 7:319–321.
79. Ward, K. W., R. Nagilla, and L. J. Jolivette. 2005. Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human. Xenobiotica 35, no. 2:191–210.
80. Wegner, K., K. A. Horais, N. A. Tozier, M. L. Rathbun, Y. Shtaerman, and T. L. Yaksh. 2008. Development of a canine nociceptive thermal escape model. J. Neurosci. Methods 168, no. 1:88–97.
81. Whiteside, G. T., A. Adedoyin, and L. Leventhal. 2008. Predictive validity of animal pain models? A comparison of the pharmacokinetic-pharmacodynamic relationship for pain drugs in rats and humans. Neuropharmacology 54, no. 5:767–775.
82. Willis, W. D. 1999. Dorsal root potentials and dorsal root reflexes: a double-edged sword. Exp. Brain Res. 124, no. 4:395–421.
83. Wiseman-Orr, M. L., A. M. Nolan, J. Reid, and E. M. Scott. 2004. Development of a questionnaire to measure the effects of chronic pain on health-related quality of life in dogs. Am. J. Vet. Res. 65, no. 8:1077–1084.
84. Wiseman-Orr, M. L., E. M. Scott, J. Reid, and A. M. Nolan. 2006. Validation of a structured questionnaire as an instrument to measure chronic pain in dogs on the basis of effects on health-related quality of life. Am. J. Vet. Res. 67, no. 11:1826–1836.
85. Zeilhofer, H. U. 2005. Synaptic modulation in pain pathways. Rev. Physiol. Biochem. Pharmacol. 154:73–100.